Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0005586
Disease: Bipolar Disorder
Bipolar Disorder 		0.350 Biomarker disease BEFREE Further studies in independent and larger cohorts are warranted to confirm the involvement of IGFBP2 in BD. 28090803 2018
CUI: C0005586
Disease: Bipolar Disorder
Bipolar Disorder 		0.350 Biomarker disease BEFREE The most common adverse event was skin rash: 22.0% for BP-I, 16.7% for BP-II, and 12.1% for BP-NOS. 28360522 2017
CUI: C0005586
Disease: Bipolar Disorder
Bipolar Disorder 		0.350 AlteredExpression disease BEFREE Decreased expression of insulin-like growth factor binding protein 2 in the prefrontal cortex of subjects with bipolar disorder and its regulation by lithium treatment. 17395163 2007
CUI: C0005586
Disease: Bipolar Disorder
Bipolar Disorder 		0.350 Biomarker disease PSYGENET We found decreased IGFBP-2 expression in bipolar disorder patients compared with controls; this was especially pronounced in subjects not treated with lithium. 17395163 2007
CUI: C0005586
Disease: Bipolar Disorder
Bipolar Disorder 		0.350 Biomarker disease PSYGENET The continuity/spectrum between BP (mainly BP-II) and MDD was supported by the following findings:(1) high frequency of mixed states (mixed mania, mixed hypomania, mixed depression, i.e. co-occurring depression and noneuphoric manic/hypomanic symptoms) because opposite polarity symptoms in the same episode do not support a hypomania/mania-depression splitting; (2) MDD was the most common mood disorder in BP probands' relatives; (3) no bimodal distribution of distinguishing symptoms between BP and MDD; (4) bipolar signs not uncommon in MDD; (5) many MDD shifting to BP; (6) many lifetime manic/hypomanic symptoms in MDD; (7) correlation between lifetime manic/hypomanic symptoms and MDD symptoms; (8) hypomania factors in MDD; (9) MDD often recurrent; (10) similar cognitive style. 17230047 2007
CUI: C0005586
Disease: Bipolar Disorder
Bipolar Disorder 		0.350 AlteredExpression disease LHGDN We found decreased IGFBP-2 expression in bipolar disorder patients compared with controls; this was especially pronounced in subjects not treated with lithium. 17395163 2007
CUI: C0005586
Disease: Bipolar Disorder
Bipolar Disorder 		0.350 Biomarker disease BEFREE The continuity/spectrum between BP (mainly BP-II) and MDD was supported by the following findings:(1) high frequency of mixed states (mixed mania, mixed hypomania, mixed depression, i.e. co-occurring depression and noneuphoric manic/hypomanic symptoms) because opposite polarity symptoms in the same episode do not support a hypomania/mania-depression splitting; (2) MDD was the most common mood disorder in BP probands' relatives; (3) no bimodal distribution of distinguishing symptoms between BP and MDD; (4) bipolar signs not uncommon in MDD; (5) many MDD shifting to BP; (6) many lifetime manic/hypomanic symptoms in MDD; (7) correlation between lifetime manic/hypomanic symptoms and MDD symptoms; (8) hypomania factors in MDD; (9) MDD often recurrent; (10) similar cognitive style. 17230047 2007
CUI: C0005586
Disease: Bipolar Disorder
Bipolar Disorder 		0.350 Biomarker disease PSYGENET Efforts to dissect BPAD have been based on the course of the disorders (BP I versus BP II or rapid cycling), comorbidity pattern (panic attacks, suicide attempts, addiction or hyperactivity), differences between the sexes, and clinical pattern (cycloid and puerperal psychosis). 15762851 2005
CUI: C0005586
Disease: Bipolar Disorder
Bipolar Disorder 		0.350 Biomarker disease BEFREE Efforts to dissect BPAD have been based on the course of the disorders (BP I versus BP II or rapid cycling), comorbidity pattern (panic attacks, suicide attempts, addiction or hyperactivity), differences between the sexes, and clinical pattern (cycloid and puerperal psychosis). 15762851 2005
CUI: C0028754
Disease: Obesity
Obesity 		0.340 PosttranslationalModification disease BEFREE To explore possible epigenetic changes of the IGFBP2 gene in obesity, we analyzed DNA methylation and mRNA expression in adipocytes from different depots. 30921666 2019
CUI: C0028754
Disease: Obesity
Obesity 		0.340 GeneticVariation disease BEFREE In addition, the PPAR-γ2-RXR-α heterodimer showed weak activity and bound weakly to the putative IGFBP-2-PPRE promoter sequence in VAT from HIR-MO subjects when compared with LIR-MO individuals. 31547433 2019
CUI: C0028754
Disease: Obesity
Obesity 		0.340 Biomarker disease BEFREE Secretion of IGFBP-1 and IGFBP-2 is further suppressed by insulin and diminished with increasing obesity. 26522454 2015
CUI: C0028754
Disease: Obesity
Obesity 		0.340 Biomarker disease CTD_human Insulin-like growth factor binding protein-2 (IGFBP2) is a key regulator of IGF activity that has been associated with insulin resistance and obesity. 22537059 2012
CUI: C0028754
Disease: Obesity
Obesity 		0.340 Biomarker disease BEFREE These findings demonstrate that the transcription of the IGFBP2 gene is modulated in a depot-specific fashion in obesity and aging in mice and men. 20730703 2010
CUI: C0010606
Disease: Adenoid Cystic Carcinoma
Adenoid Cystic Carcinoma 		0.310 Biomarker disease BEFREE IGFBP2 promotes salivary adenoid cystic carcinoma metastasis by activating the NF-κB/ZEB1 signaling pathway. 29885520 2018
CUI: C0010606
Disease: Adenoid Cystic Carcinoma
Adenoid Cystic Carcinoma 		0.310 Biomarker disease CTD_human Genes associated with early development, apoptosis and cell cycle regulation define a gene expression profile of adenoid cystic carcinoma. 16762588 2006
CUI: C0023890
Disease: Liver Cirrhosis
Liver Cirrhosis 		0.300 Biomarker disease CTD_human Gene Expression Patterns Associated With Histopathology in Toxic Liver Fibrosis. 26396155 2016
CUI: C0239946
Disease: Fibrosis, Liver
Fibrosis, Liver 		0.300 Biomarker disease CTD_human Gene Expression Patterns Associated With Histopathology in Toxic Liver Fibrosis. 26396155 2016
CUI: C0011616
Disease: Contact Dermatitis
Contact Dermatitis 		0.300 Biomarker disease CTD_human Genes specifically modulated in sensitized skins allow the detection of sensitizers in a reconstructed human skin model. Development of the SENS-IS assay. 25724174 2015
CUI: C0162351
Disease: Contact hypersensitivity
Contact hypersensitivity 		0.300 Biomarker phenotype CTD_human Genes specifically modulated in sensitized skins allow the detection of sensitizers in a reconstructed human skin model. Development of the SENS-IS assay. 25724174 2015
CUI: C0023893
Disease: Liver Cirrhosis, Experimental
Liver Cirrhosis, Experimental 		0.300 Biomarker disease CTD_human Systems level analysis and identification of pathways and networks associated with liver fibrosis. 25380136 2014
CUI: C0021655
Disease: Insulin Resistance
Insulin Resistance 		0.300 Biomarker phenotype CTD_human Insulin-like growth factor binding protein-2 (IGFBP2) is a key regulator of IGF activity that has been associated with insulin resistance and obesity. 22537059 2012
CUI: C0920563
Disease: Insulin Sensitivity
Insulin Sensitivity 		0.300 Biomarker phenotype CTD_human Associations between bovine IGFBP2 polymorphisms with fertility, milk production, and metabolic status in UK dairy cows. 22537059 2012
CUI: C0023893
Disease: Liver Cirrhosis, Experimental
Liver Cirrhosis, Experimental 		0.300 Biomarker disease CTD_human Gene expression profiles of hepatic cell-type specific marker genes in progression of liver fibrosis. 17072980 2006
CUI: C0036095
Disease: Salivary Gland Neoplasms
Salivary Gland Neoplasms 		0.300 Biomarker group CTD_human Genes associated with early development, apoptosis and cell cycle regulation define a gene expression profile of adenoid cystic carcinoma. 16762588 2006